about
Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphomaCritical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.The use of microarray technologies in mantle cell lymphoma.Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia.Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue SarcomaPiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in miceDissection of gene expression datasets into clinically relevant interaction signatures via high-dimensional correlation maximization
P50
Q30375911-C766E231-E4A0-4ED0-8BB1-9EA2269F9391Q34211312-C247AC02-DFD1-4A7C-87E0-A7BA56702A98Q34408939-0AD414ED-CFA2-45D0-B359-4D0383FD8251Q34472091-7073E9F9-CBF3-450E-95DD-81405B2C5728Q35493964-4731EA84-1C34-42F9-AC0F-DD0CAFB3D9EBQ36890570-A5968EC1-C8D4-4408-B9FB-55D7783862DCQ37904047-C5C3D398-E958-4AE5-92BF-420BA98196FBQ38716342-EE8E6928-4348-4AEA-8E84-043CC5A12D86Q38943591-669BA901-FDDA-4CB2-A064-ED56EB991350Q39226671-00201DD3-B4CB-41D6-99D8-0BBFB2BD4FB3Q39443070-10F3C0DD-4B9C-4464-99BE-0FECBF2AA40FQ40467460-BD3E0B58-DDC2-40DB-B968-A682217AB2ACQ43963203-6F324748-0F09-4C2C-A360-D7FC55B57675Q48222343-7B478DE3-3D3D-4637-A519-BEF5C12596F7Q50105551-5FBF0439-AE23-4346-A1DD-15351DD97641Q52806518-3D7AC34F-C193-4EB2-BF08-D020CFBD11C4Q52873636-3A31CE25-E83F-4BF6-8C34-960BA600A19BQ52885667-EDD801FE-57DD-4910-B88C-1361E5D48685Q54560322-02378F21-15BC-442D-B67E-142E1BF6C720Q58768458-46BD0291-1569-4837-BD55-FDA77711CBDBQ64104353-DD5D2C55-4DF4-413C-9349-62DE4EEE267CQ91525264-D548FDA4-B04B-4639-84A2-F40054E15BE8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Grau
@ast
Michael Grau
@en
Michael Grau
@es
Michael Grau
@nl
Michael Grau
@sl
type
label
Michael Grau
@ast
Michael Grau
@en
Michael Grau
@es
Michael Grau
@nl
Michael Grau
@sl
prefLabel
Michael Grau
@ast
Michael Grau
@en
Michael Grau
@es
Michael Grau
@nl
Michael Grau
@sl
P106
P2038
Michael_Grau
P21
P31
P496
0000-0003-1909-0133